Clinical Trials Logo

Infections clinical trials

View clinical trials related to Infections.

Filter by:

NCT ID: NCT06448624 Recruiting - Biomarkers Clinical Trials

Biomarkers & Infection After Prophylactic Antibiotic in Cardiac Implantable Electronic Device Implantation

BI-PACED
Start date: April 1, 2024
Phase: Phase 4
Study type: Interventional

Effect of single dose & intrapocket prophylactic antibiotic to cardiac implantable electronic device-related infection & biomarkers

NCT ID: NCT06440564 Enrolling by invitation - Clinical trials for Periprosthetic Joint Infections

Laser Disinfection in Periprosthetic Joint Infection

Start date: November 1, 2021
Phase: N/A
Study type: Interventional

The eradication of biofilms from infected implants is still an unsolved challenge. The high-energy light beam of an Er:YAG laser causes rapid heating and explosive ablation of tissue. In this study we test the suitability of this laser for the removal of biofilms from infected implant surfaces.

NCT ID: NCT06440304 Not yet recruiting - Clinical trials for Infections, Bacterial

Therapeutic Options for CRAB

TheraCRAB
Start date: November 2024
Phase: Phase 4
Study type: Interventional

CRAB infections in ICUs are on the rise, leading to higher morbidity, mortality, and healthcare costs due to resistance to most antibiotics, including carbapenems. The main resistance mechanisms include carbapenemases, efflux pumps, and changes in the bacterial cell wall. Current treatments include polymyxins (Colistin, Polymyxin B), which are effective but can lead to resistance, aminoglycosides (Amikacin, Gentamicin), which are limited by resistance, and tetracyclines (Tigecycline, Eravacycline), which are effective against CRAB. Fosfomycin is effective in combination treatments, and combination therapy (e.g., colistin with sulbactam, fosfomycin, or eravacycline) can enhance outcomes. Previous research shows promise for combination therapies, improving treatment efficacy and reducing mortality. New regimens are being studied to find optimal combinations. Individualized dosing is crucial, considering patient-specific factors like age, weight, and renal function. Adjustments depend on the infection site and comorbidities. Strict infection control and antimicrobial stewardship programs (ASPs) are essential. ASPs focus on optimizing antibiotic use and reducing resistance through education and surveillance. Future directions include continued research for new drugs or combinations and strategies to overcome resistance and improve treatment efficacy. Study goals include achieving negative samples after 10 days of therapy, 30-day survival, discharge rates, reduced SOFA scores, and improved clinical and radiological findings. A randomized study will compare colistin combined with fosfomycin, ampicillin/sulbactam, and eravacycline. In summary, treating CRAB infections is complex, requiring combination therapy, individualized dosing, and strict infection control measures.

NCT ID: NCT06439953 Not yet recruiting - Clinical trials for Surgical Site Infection

Impact of Prophylactic Use of Irrisept Irrigation System for Spinal Instrumentation

Start date: June 2024
Phase: N/A
Study type: Interventional

Various spine surgeons perform wound irrigation using saline mixed with vancomycin, relying on mechanical debridement of non-viable tissue, physical disruption of biofilm, and bacteriostatic effect against gram positive flora. When used as a powder, topical application of vancomycin has demonstrated increased risk of symptomatic seroma formation, which is an adverse outcome that often requires bedside or intra-operative aspiration. Broad-spectrum antiseptic agents, such as Irrisept, offer bacteriocidal properties to eliminate hardware inoculation, thereby minimizing the risk of deep space infection, while obviating the risk of seroma development.

NCT ID: NCT06439433 Completed - Clinical trials for Papillomavirus Infections

ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection

Start date: May 31, 2021
Phase: Phase 2
Study type: Interventional

Efficacy and Safety of ALA-PDT in patients with cervical intraepithelial neoplasia grade 2 (CIN2) in p16-positivity and high-risk HPV infection.

NCT ID: NCT06437379 Active, not recruiting - Kidney Stone Clinical Trials

Infection Control Measures for Patients Undergoing Percutaneous Nephrolithotomy

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

To evaluate the effect of implementing teaching protocol on nurse's knowledge and practice regarding infection control measures for patients undergoing Percutaneous Nephrolithotomy.

NCT ID: NCT06435403 Recruiting - Clinical trials for SARS CoV 2 Infection

SARS-CoV-2 Specific Antibody Responses and Impact for COVID-19 Disease in Ethiopia

CoVICIS
Start date: November 10, 2022
Phase:
Study type: Observational

In this study we aim to characterize SARS CoV-2 strain specific immune response (SARS-CoV-2 Spike IgG) in health care workers and general populations at the Jimma Medical Center and the St. Paul Hospital in Addis Ababa in association to clinical immune protection and Covid-19 disease. Participants, stratified by SARS-CoV-2 infection and vaccination status, will be followed at 3-month intervals for a maximum of 2 years. Prevalence, incidence, and dynamics of SARS-CoV-2 specific antibodies as well as clinical assessments especially related to COVID-19 breakthrough disease in previously exposed/vaccinated participants will be performed. From a subset of selected participant blood sample, more in depth immunological analysis will be performed that include virus culture-based neutralization assays, antibody avidity assays, SARS-CoV-2 specific antibody epitope recognition using peptide arrays, and T-cell immunity assays (IGRA). We also plan to analyze and model cost-effectiveness considerations related to adapted COVID-19 vaccine strategies, specifically if SARS-CoV-2 the costs for routine sero-diagnosis in high SARS-CoV-2 prevalent population prior to vaccination will impact the decision to vaccinate (no vaccination for low-risk populations or reduced vaccine dosing) and is cost-efficient. The study is largely exploratory, providing deeper insights in SARS-CoV-2 specific immune responses and interaction with SARS-CoV-2 viral variants.

NCT ID: NCT06433128 Available - Clinical trials for Invasive Fungal Infections

Expanded Access to Fosmanogepix for Patients With Serious or Life-threatening Invasive Fungal Infections

Start date: n/a
Phase:
Study type: Expanded Access

The EAP is intended to provide a treatment option for patients with proven or probable serious or life-threatening invasive fungal infection (in accordance with the EORTC-MSGERC criteria) who have exhausted their treatment options, primarily due to an infection with a resistant fungal pathogen, and for whom no other treatment options are available through marketed drugs or investigational agents in clinical studies ongoing in the respective indication.

NCT ID: NCT06431412 Active, not recruiting - Critical Illness Clinical Trials

A Model for Drug Concentration Prediction of Vancomycin

Start date: March 1, 2024
Phase:
Study type: Observational

Objective: This study aims to use machine learning methods to establish an optimal model for predicting serum vancomycin trough concentrations in critically ill patients. Methods: This is a single-center, retrospective study. Data on serum vancomycin concentration in the Critical Care Database of Peking Union Medical College Hospital were screened and extracted to construct a prediction model using machine learning methods. The MIMIC-IV (Medical Information Mart for Intensive Care) database will be further used for external verification of the constructed model. The study has been approved by the Medical Ethics Committee of Peking Union Medical College Hospital (K24C1161).

NCT ID: NCT06431217 Completed - Clinical trials for Maternal Health, Child Health, Infectious Diseases

Group B Strep Correlates of Protection Study

GBSCoP
Start date: March 1, 2019
Phase:
Study type: Observational

Streptococcus agalactiae or Group B Streptococcus (GBS) is a leading cause of neonatal sepsis in developed and developing countries. The study aims to bolster the evidence base of establishing a sero-correlate of protection against invasive GBS disease in infants. These sero-correlates of protection will be used to study the effectiveness of GBS vaccine against invasive disease.